4-Isopropyl-2-methyl-pyrrolidin | 13603-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-Isopropyl-2-methyl-pyrrolidin
• 英文别名: 4-isopropyl-2-methyl-pyrrolidine；2-Methyl-4-isopropylpyrrolidine；2-methyl-4-propan-2-ylpyrrolidine
• CAS: 13603-16-2
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: BAGNGDSSIAISMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases
  申请人：Brodney Michael A.

  公开号：US20110046160A1

  公开（公告）日：2011-02-24

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物及其药用可接受盐，其中该化合物具有规范中定义的公式（I）的结构。同时还公开了相应的药物组合物、治疗方法、合成方法和中间体。
• Novel Lactams as Beta Secretase Inhibitors
  申请人：Brodney Michael A.

  公开号：US20110224231A1

  公开（公告）日：2011-09-15

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment methods of synthesis, and intermediates are also disclosed.

  本发明揭示了具有以下式子(I)结构的化合物及其在药学上可接受的盐。同时还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US20160362410A1

  公开（公告）日：2016-12-15

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds (referred to herein as “PPDA compounds”) that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; and cardiovascular disorders (including atherosclerosis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
• US9932344B2
  申请人：——

  公开号：US9932344B2

  公开（公告）日：2018-04-03
• [EN] HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION<br/>[FR] PRÉCURSEURS CONTENANT DU HAFNIUM POUR UN DÉPÔT EN PHASE VAPEUR
  申请人：AIR LIQUIDE

  公开号：WO2013177284A1

  公开（公告）日：2013-11-28

  Disclosed are hafnium-containing precursors and methods of synthesizing the same. The precursors may be used to deposit hafnium oxide, hafnium silicon oxide and hafnium-metal oxide containing layers using vapor deposition methods such as chemical vapor deposition or atomic layer deposition.